ETF Managers Group’s Myriad Genetics MYGN Stock Holding History

ETF Managers Group’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-21,976	Closed	-$405K	–	774
2022 Q2	$405K	Buy	+21,976	New	+$456K	0.01%	547
2021 Q2	–	Sell	-9,405	Closed	-$274K	–	754
2021 Q1	$274K	Buy	+9,405	New	+$267K	﹤0.01%	594

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return

ETF Managers Group's MYGN Position: Q3 2022 in Review

ETF Managers Group sold out of Myriad Genetics (MYGN) in Q3 2022, closing a stake of 21,976 shares — an estimated $405K sold.

ETF Managers Group first reported a position in MYGN in Q1 2021 and held it in 2 quarters. The position peaked at $405K in Q2 2022. 191 funds tracked by Wall St. Rank hold MYGN as of Q3 2022.

ETF Managers Group reported no remaining Myriad Genetics position as of Q3 2022 after selling out during the quarter.
ETF Managers Group sold 21,976 Myriad Genetics shares in Q3 2022, an estimated $405K.
ETF Managers Group first reported a position in Myriad Genetics in Q1 2021 and held it in 2 quarters.
ETF Managers Group's Myriad Genetics position peaked at $405K in Q2 2022.
191 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2022.

Based on ETF Managers Group's 13F filing for Q3 2022, filed 14 Nov 2022.